Global Neurodegenerative Disease Market Size, Share, Growth Analysis Report - Forecast 2034

Neurodegenerative Disease Market

Neurodegenerative Disease Market By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington’s Disease, and Other Indication Types), By Drug Type (N-methyl-D-Aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, and Other Drug Types), and By Region: Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034-

Category: Healthcare Report Format : PDF Pages: 241 Report Code: ZMR-2147 Published Date: Apr-2025 Status : Published
Market Size in 2024 Market Forecast in 2034 CAGR (in %) Base Year
USD 61.93 Billion USD 121.30 Billion 7.1% 2024

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Neurodegenerative Disease Market, (2022 - 2028) (USD Million)
    • 2.2 Global Neurodegenerative Disease Market : snapshot
  • Chapter 3. Global Neurodegenerative Disease Market - Industry Analysis
    • 3.1 Neurodegenerative Disease Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Prevalence of Alzheimer’s Disease Drives Market Growth
    • 3.3 Market Restraints
      • 3.3.1. Inadequate reimbursement policies may hamper the global market growth.
    • 3.4 Market Opportunities
      • 3.4.1. A robust drug pipeline for treating neurodegenerative diseases brings up several growth opportunities.
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Indication Type
      • 3.7.2 Market attractiveness analysis By Drug Type
  • Chapter 4. Global Neurodegenerative Disease Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Neurodegenerative Disease Market: company market share, 2021
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Neurodegenerative Disease Market - Indication Type Analysis
    • 5.1 Global Neurodegenerative Disease Market overview: By Indication Type
      • 5.1.1 Global Neurodegenerative Disease Market share, By Indication Type, 2021 and 2028
    • 5.2 Parkinson's Disease
      • 5.2.1 Global Neurodegenerative Disease Market by Parkinson's Disease, 2022 - 2028 (USD Million)
    • 5.3 Alzheimer's Disease
      • 5.3.1 Global Neurodegenerative Disease Market by Alzheimer's Disease, 2022 - 2028 (USD Million)
    • 5.4 Multiple Sclerosis
      • 5.4.1 Global Neurodegenerative Disease Market by Multiple Sclerosis, 2022 - 2028 (USD Million)
    • 5.5 Huntington Disease
      • 5.5.1 Global Neurodegenerative Disease Market by Huntington Disease, 2022 - 2028 (USD Million)
    • 5.6 Other Indication Types
      • 5.6.1 Global Neurodegenerative Disease Market by Other Indication Types, 2022 - 2028 (USD Million)
  • Chapter 6. Global Neurodegenerative Disease Market - Drug Type Analysis
    • 6.1 Global Neurodegenerative Disease Market overview: By Drug Type
      • 6.1.1 Global Neurodegenerative Disease Market share, By Drug Type, 2021 and 2028
    • 6.2 N-methyl-D-aspartate Receptor antagonists
      • 6.2.1 Global Neurodegenerative Disease Market by N-methyl-D-aspartate Receptor antagonists, 2022 - 2028 (USD Million)
    • 6.3 Cholinesterase Inhibitors
      • 6.3.1 Global Neurodegenerative Disease Market by Cholinesterase Inhibitors, 2022 - 2028 (USD Million)
    • 6.4 Dopamine Agonists
      • 6.4.1 Global Neurodegenerative Disease Market by Dopamine Agonists, 2022 - 2028 (USD Million)
    • 6.5 Immunomodulatory Drugs
      • 6.5.1 Global Neurodegenerative Disease Market by Immunomodulatory Drugs, 2022 - 2028 (USD Million)
    • 6.6 Other Drug Types
      • 6.6.1 Global Neurodegenerative Disease Market by Other Drug Types, 2022 - 2028 (USD Million)
  • Chapter 7. Neurodegenerative Disease Market - Regional Analysis
    • 7.1 Global Neurodegenerative Disease Market Regional Overview
    • 7.2 Global Neurodegenerative Disease Market Share, by Region, 2021 & 2028 (USD Million)
    • 7.3. North America
      • 7.3.1 North America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
        • 7.3.1.1 North America Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 North America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
      • 7.4.1 North America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
    • 7.5 North America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
      • 7.5.1 North America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
    • 7.4. Europe
      • 7.4.2 Europe Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
        • 7.4.2.1 Europe Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 Europe Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
      • 7.4.1 Europe Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
    • 7.5 Europe Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
      • 7.5.1 Europe Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
    • 7.5. Asia Pacific
      • 7.5.3 Asia Pacific Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
        • 7.5.3.1 Asia Pacific Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 Asia Pacific Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
      • 7.4.1 Asia Pacific Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
    • 7.5 Asia Pacific Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
      • 7.5.1 Asia Pacific Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
    • 7.6. Latin America
      • 7.6.4 Latin America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
        • 7.6.4.1 Latin America Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 Latin America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
      • 7.4.1 Latin America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
    • 7.5 Latin America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
      • 7.5.1 Latin America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
    • 7.7. The Middle-East and Africa
      • 7.7.5 The Middle-East and Africa Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
        • 7.7.5.1 The Middle-East and Africa Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 The Middle-East and Africa Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
      • 7.4.1 The Middle-East and Africa Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
    • 7.5 The Middle-East and Africa Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
      • 7.5.1 The Middle-East and Africa Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1 Biogen Inc
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Abbvie Inc
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 UCB SA
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Amneal Pharmaceuticals Inc
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Teva Pharmaceuticals Ltd
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Boehringer Ingelheim International GmbHF
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Pfizer Inc
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Hoffmann-La Roche
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 Novartis AG
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 Merck & Co. Inc.
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Neurodegenerative Disease Market attractiveness, By Indication Type
  • 6. Global Neurodegenerative Disease Market attractiveness, By Drug Type
  • 7. Global Neurodegenerative Disease Market share by Indication Type, 2022 and 2028 (USD Million)
  • 8. Global Neurodegenerative Disease Market by Parkinson's Disease, 2022 - 2028 (USD Million)
  • 9. Global Neurodegenerative Disease Market by Alzheimer's Disease, 2022 - 2028 (USD Million)
  • 10. Global Neurodegenerative Disease Market by Multiple Sclerosis, 2022 - 2028 (USD Million)
  • 11. Global Neurodegenerative Disease Market by Huntington Disease, 2022 - 2028 (USD Million)
  • 12. Global Neurodegenerative Disease Market by Other Indication Types, 2022 - 2028 (USD Million)
  • 13. Global Neurodegenerative Disease Market share by Drug Type, 2022 and 2028 (USD Million)
  • 14. Global Neurodegenerative Disease Market by N-methyl-D-aspartate Receptor antagonists, 2022 - 2028 (USD Million)
  • 15. Global Neurodegenerative Disease Market by Cholinesterase Inhibitors, 2022 - 2028 (USD Million)
  • 16. Global Neurodegenerative Disease Market by Dopamine Agonists, 2022 - 2028 (USD Million)
  • 17. Global Neurodegenerative Disease Market by Immunomodulatory Drugs, 2022 - 2028 (USD Million)
  • 18. Global Neurodegenerative Disease Market by Other Drug Types, 2022 - 2028 (USD Million)
  • 19. Global Neurodegenerative Disease Market share, by Region, 2022 and 2028
  • 20. North America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
  • 21. Europe Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
  • 22. Asia Pacific Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
  • 23. Latin America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
  • 24. The Middle-East and Africa Neurodegenerative Disease Market, 2022 - 2028 (USD Million)

Table Of Tables

  • 1. Global Neurodegenerative Disease Market: Snapshot
  • 2. Drivers of the Neurodegenerative Disease Market: impact analysis
  • 3. North America Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 4. North America Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 5. U.S. Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 6. U.S. Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 7. Canada Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 8. Canada Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 9. Europe Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 10. Europe Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 11. Germany Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 12. Germany Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 13. France Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 14. France Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 15. U.K. Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 16. U.K. Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 17. Italy Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 18. Italy Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 19. Spain Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 20. Spain Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 21. Rest of Europe Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 22. Rest of Europe Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 23. Asia Pacific Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 24. Asia Pacific Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 25. China Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 26. China Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 27. Japan Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 28. Japan Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 29. India Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 30. India Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 31. South Korea Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 32. South Korea Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 33. South-East Asia Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 34. South-East Asia Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 35. Rest of Asia Pacific Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 36. Rest of Asia Pacific Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 37. Latin America Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 38. Latin America Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 39. Brazil Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 40. Brazil Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 41. Mexico Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 42. Mexico Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 43. Rest of Latin America Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 44. Rest of Latin America Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 45. The Middle-East and Africa Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 46. The Middle-East and Africa Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 47. GCC Countries Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 48. GCC Countries Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 49. South Africa Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 50. South Africa Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
  • 51. Rest of Middle-East Africa Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
  • 52. Rest of Middle-East Africa Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)

Methodology

FrequentlyAsked Questions

The global neurodegenerative disease market is expected to grow due to increasing prevalence of neurodegenerative disorders, and ongoing advancements in research and drug development targeting these conditions.

According to a study, the global neurodegenerative disease market size was worth around USD 61.93 Billion in 2024 and is expected to reach USD 121.30 Billion by 2034.

The global neurodegenerative disease market is expected to grow at a CAGR of 7.1% during the forecast period.

North America is expected to dominate the neurodegenerative disease market over the forecast period.

Leading players in the global neurodegenerative disease market include Biogen Inc, Abbvie Inc, UCB SA, Amneal Pharmaceuticals Inc, Teva Pharmaceuticals Ltd, Boehringer Ingelheim International GmbHF, Pfizer Inc, Hoffmann-La Roche, Novartis AG, Merck & Co. Inc, among others

The report explores crucial aspects of the neurodegenerative disease market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.

  • zion payment modes

List of Contents

Market SizeOverviewKey InsightsGrowth DriversRestraintsOpportunitiesChallengesSegmentation AnalysisReport ScopeRecent DevelopmentsRegional LandscapeCompetitive Analysis

HappyClients